Bright Minds Biosciences Inc. (DRUG) Key Metrics
DRUG key metrics, FY2019–FY2025
Fiscal year ended September 30, 2025 · Canadian dollarsDRUG returns How much profit the business earns on the capital it uses.
DRUG financial health Debt, liquidity and how easily interest is covered.
DRUG efficiency & capital use Working capital cycle and where the cash goes.
DRUG returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
DRUG debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
DRUG key metrics in Canadian dollars
FY2019–FY2025| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Returns & profitability | |||||||
| Return on equity (ROE) | −27.9% | −46.2% | −86.0% | −100.0% | −84.6% | −113.5% | −185.6% |
| Return on invested capital (ROIC) | — | — | — | — | — | — | −394.7% |
| Return on assets (ROA) | −27.0% | −43.2% | −77.7% | −93.2% | −81.4% | −93.1% | −144.0% |
| Return on tangible assets | −14.5% | −45.9% | −107.2% | −123.8% | −42.5% | −55.3% | −145.8% |
| Financial health | |||||||
| Total debt | C$125,777 | C$118,960 | C$73,549 | C$139,911 | — | — | — |
| Cash & short-term investments | C$82.9M | C$5.7M | C$6.7M | C$11.6M | C$19.8M | C$799,929 | C$79,991 |
| Net debt | −C$82.8M | −C$5.6M | −C$6.7M | −C$11.5M | −C$19.8M | −C$799,929 | −C$79,991 |
| Debt / equity | 0.00 | 0.02 | 0.01 | 0.01 | — | — | — |
| Debt / assets | 0.00 | 0.02 | 0.01 | 0.01 | — | — | — |
| Current ratio | 36.10 | 11.32 | 24.26 | 8.11 | 31.38 | 5.82 | 2.18 |
| Quick ratio | 36.10 | 11.32 | 24.39 | 8.11 | 31.38 | 5.82 | 2.18 |
| Interest coverage | -541.5 | — | -374.0 | -67.2 | — | — | — |
| Working capital | C$82.0M | C$5.5M | C$6.5M | C$10.5M | C$19.4M | C$727,293 | C$43,283 |
| Invested capital | −C$737,889 | −C$64,789 | −C$76,221 | −C$945,490 | −C$358,220 | −C$70,636 | C$47,271 |
| Tangible asset value | C$82.0M | C$5.5M | C$6.6M | C$10.5M | C$19.4M | C$727,293 | C$125,263 |
| Net current asset value | C$81.9M | C$5.4M | C$6.5M | C$10.4M | C$19.4M | C$727,293 | C$43,283 |
| Capital allocation | |||||||
| Capex / depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | |||||||
| Days of inventory on hand | — | — | -186.3 | — | — | — | — |
| Days payables outstanding | 7,003.1 | — | 3,598.8 | 55,713.0 | — | — | — |
| Receivables turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| Payables turnover | 0.05 | — | 0.10 | 0.01 | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | C$231,648 | C$43,602 | C$96,380 | C$132,962 | C$110,146 | — | — |
| Average payables | C$1.1M | C$294,928 | C$714,346 | C$921,478 | C$367,498 | C$87,566 | C$36,708 |
| Average inventory | — | — | −C$36,981 | — | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 1.2% |
Computed from DRUG's annual financial statements (latest annual report filed December 23, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in Canadian dollars; data from EODHD. Averages use the opening and closing balance of each year.
DRUG valuation and financial ratios
Bright Minds Biosciences earned a return on equity of −27.9% in fiscal 2025. It ended the year with C$0.1 million of debt and C$82.9 million in cash and short-term investments, a net cash position of C$82.8 million.
See the DRUG income statement, the DRUG chart for price history, or the DRUG stock overview for the latest quote and news.
DRUG key metrics FAQ
What is Bright Minds Biosciences's return on equity?
Bright Minds Biosciences's return on equity (ROE) was −27.9% in fiscal 2025: net income of -C$12.2 million on average shareholders' equity of C$43.8 million.
How much debt does Bright Minds Biosciences have?
Bright Minds Biosciences had total debt of C$0.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Bright Minds Biosciences's current ratio?
Bright Minds Biosciences's current ratio was 36.10 at the end of fiscal 2025: current assets were 36.10 times current liabilities.